Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PREZCOBIX | Johnson & Johnson | N-205395 RX | 2015-01-29 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PREZISTA | Johnson & Johnson | N-021976 RX | 2008-02-25 | 4 products, RLD |
PREZISTA | Johnson & Johnson | N-202895 RX | 2011-12-16 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SYMTUZA | Johnson & Johnson | N-210455 RX | 2018-07-17 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
darunavir | ANDA | 2025-03-19 |
darunavir 600 and 800 mg | ANDA | 2024-01-18 |
prezcobix | New Drug Application | 2024-07-23 |
prezista | New Drug Application | 2024-07-23 |
symtuza | New Drug Application | 2024-07-23 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Cobicistat / Darunavir / Emtricitabine / Tenofovir Alafenamide Fumarate, Symtuza, Janssen Prods | |||
10786518 | 2038-07-19 | U-2978 | |
8754065 | 2032-08-15 | DS, DP | U-2352, U-2765 |
9296769 | 2032-08-15 | DS, DP | U-2352, U-2765 |
7390791 | 2025-04-17 | DS, DP | |
Cobicistat / Darunavir, Prezcobix, Janssen Prods | |||
10039718 | 2032-10-06 | DP | |
8148374 | 2029-09-03 | DS, DP | U-1279, U-2353, U-2364, U-2365, U-2766, U-2767, U-2768, U-2939 |
7700645 | 2026-12-26 | DS, DP | |
8518987 | 2024-02-16 | DS, DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | 9 | 5 | 1 | 17 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | 6 | 2 | — | 9 |
Hiv-1 | D015497 | — | — | 2 | — | 2 | 1 | — | 5 |
Hiv | D006678 | — | O98.7 | 1 | — | 3 | 1 | — | 5 |
Infections | D007239 | EFO_0000544 | — | — | — | — | 2 | — | 2 |
Weight gain | D015430 | — | — | — | — | — | 1 | — | 1 |
Hiv seropositivity | D006679 | — | — | — | — | — | 1 | — | 1 |
Communicable diseases | D003141 | — | — | — | — | — | 1 | — | 1 |
Viremia | D014766 | — | B34.9 | — | — | — | 1 | — | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Immunologic deficiency syndromes | D007153 | — | D84.9 | 1 | — | 4 | — | — | 5 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
Hiv-2 | D015498 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Darunavir |
INN | darunavir |
Description | Darunavir is an N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors. It has a role as a HIV protease inhibitor and an antiviral drug. It is a furofuran, a carbamate ester and a sulfonamide. |
Classification | Small molecule |
Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1 |
PDB | — |
CAS-ID | 206361-99-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1323 |
ChEBI ID | 367163 |
PubChem CID | 213039 |
DrugBank | DB01264 |
UNII ID | YO603Y8113 (ChemIDplus, GSRS) |